# OnCo record cdkn2a (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/cdkn2a/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "cdkn2a" ;
  schema:name "CDKN2A"@en ;
  schema:alternateName "cyclin dependent kinase inhibitor 2A"@en, "Cyclin-dependent kinase inhibitor 2A"@en, "CDK4I"@en, "p16"@en, "INK4a"@en, "MTS1"@en, "CMM2"@en, "p19"@en, "p14"@en, "INK4"@en, "p16INK4a"@en, "p19Arf"@en, "p14ARF"@en, "P16-INK4A"@en, "CAI2"@en, "CDKN2"@en, "CDKN2A" ;
  schema:description "CDKN2A (Cyclin-dependent kinase inhibitor 2A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Bladder & urothelial cancer and 5 more."@en ;
  schema:url <https://onco.cc/targets/cdkn2a/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1787>, <https://www.uniprot.org/uniprotkb/P42771/entry>, <https://www.ncbi.nlm.nih.gov/gene/1029>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147889>, <https://doi.org/10.1182/blood-2017-04-779736>, <https://doi.org/10.1182/blood-2010-09-302174> ;
  onco:tag "cancer-genes-wave" ;
  onco:targetClass "tumor-suppressor" ;
  onco:firstDescribed "1993"^^xsd:gYear ;
  schema:sameAs <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1787>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147889>, <https://www.uniprot.org/uniprotkb/P42771/entry>, <https://www.ncbi.nlm.nih.gov/gene/1029> ;
  onco:related <https://onco.cc/collections/civic/>, <https://onco.cc/collections/open-targets/>, <https://onco.cc/collections/intogen/> ;
  onco:cancers <https://onco.cc/cancers/skin-cancer/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/leukaemia/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/urovysion/> ;
  onco:pathways <https://onco.cc/pathways/bladder-cancer-signalling/>, <https://onco.cc/pathways/cell-cycle-engine-cdks/>, <https://onco.cc/pathways/cml-signalling/>, <https://onco.cc/pathways/glioma-signalling/>, <https://onco.cc/pathways/hepatocellular-carcinoma-signalling/>, <https://onco.cc/pathways/melanoma-signalling/>, <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/>, <https://onco.cc/pathways/senescence/>, <https://onco.cc/pathways/p53-mdm2-axis/>, <https://onco.cc/pathways/chromosomal-instability/> ;
  onco:terms <https://onco.cc/terms/cdkn2a-homozygous-deletion/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-qian-driver-genes-outcomes-resected-pancreatic-jama-oncol-2018/>, <https://onco.cc/key-papers/paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018/>, <https://onco.cc/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/>, <https://onco.cc/key-papers/paper-javle-biliary-ngs-cancer-2016/>, <https://onco.cc/key-papers/paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025/>, <https://onco.cc/key-papers/paper-tcga-lung-squamous-nature-2012/> .